Results 121 to 130 of about 1,442,988 (353)

Engineering a novel IgG-like bispecific antibody against enterovirus A71

Biochemistry and Biophysics Reports, 2020
Frequent outbreaks of enterovirus A71 (EVA71) occur in the Asia-Pacific area, and these are closely associated with severe neurological symptoms in young children. No effective antiviral therapy is currently available for the treatment of EVA71 infection.
Hsiang-Ching Wang, Hui-Chen Hung, Peng-Nien Huang, Yu-An Kung, Sung-Nien Tseng, Yun-Ming Wang, Shin-Ru Shih, John Tsu-An Hsu   +7 more
doaj  

Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. [PDF]

, 1993
Louis M. Weiner, Michele Holmes, A Richeson, Antony Godwin, Gregory P. Adams, Sylvia T. Hsieh-Ma, David B. Ring, R. Katherine Alpaugh   +7 more
openalex   +1 more source

Harnessing Viral Proteases for Cellular and Molecular Engineering

Chemistry–Methods, EarlyView.
Engineered viral proteases (VIPs) provide programmable control of protein function with high specificity and low toxicity. Integrated with chemogenetic and optogenetic modules, these VIP systems enable logic gate manipulation for targeted regulation of cell signaling, gene expression, protein secretion, and degradation, thereby offering versatile ...
Mingguang Cui, Tien‐Hung Lan, Yubin Zhou   +2 more
wiley   +1 more source

Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies

mAbs
Bispecific antibodies, including bispecific IgG, are emerging as an important new class of antibody therapeutics. As a result, we, as well as others, have developed engineering strategies designed to facilitate the efficient production of bispecific IgG ...
Wen-Ting K. Tsai, Yinyin Li, Zhaojun Yin, Peter Tran, Qui Phung, Zhenru Zhou, Kun Peng, Dan Qin, Sien Tam, Christoph Spiess, Jochen Brumm, Manda Wong, Zhengmao Ye, Patrick Wu, Sivan Cohen, Paul J. Carter   +15 more
doaj   +1 more source

Anti-CD3:anti-IL-2 receptor bispecific monoclonal antibody. Targeting of activated T cells in vitro. [PDF]

, 1993
James A. MacLean, Zhen Su, Y. Guo, M S Sy, R B Colvin, Johnson T. Wong   +5 more
openalex   +1 more source

ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy

OncoImmunology, 2018
The redirection of T cell activity using bispecific antibodies is one of the most promising cancer immunotherapy approaches currently in development, but it is limited by cytokine storm-related toxicities, as well as the pharmacokinetics and tumor ...
Seandean Lykke Harwood, Ana Alvarez-Cienfuegos, Natalia Nuñez-Prado, Marta Compte, Sara Hernández-Pérez, Nekane Merino, Jaume Bonet, Rocio Navarro, Paul M. P. Van Bergen en Henegouwen, Simon Lykkemark, Kasper Mikkelsen, Kasper Mølgaard, Frederic Jabs, Laura Sanz, Francisco J. Blanco, Pedro Roda-Navarro, Luis Alvarez-Vallina   +16 more
doaj   +1 more source

A Novel Two‐Part Mixture Model for the Incidence and Time Course of Cytokine Release Syndrome After Elranatamab Dosing in Multiple Myeloma Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Cytokine release syndrome (CRS) is a common, acute adverse event associated with T‐cell redirecting therapies such as bispecific antibodies (BsAbs). The nature of CRS events data makes it challenging to capture an unbiased exposure–response relationship with commonly used models.
Donald Irby, Jennifer Hibma, Mohamed Elmeliegy, Diane Wang, Erik Vandendries, Kamrine Poels, Blerta Shtylla, Jason H. Williams   +7 more
wiley   +1 more source

Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. [PDF]

, 1991
Jan Brissinck, C. Demanet, M. Moser, Oberdan Léo, K Thielemans   +4 more
openalex   +1 more source

IQ Survey Results on Current Industry Practices—Part 1: Immunogenicity Risk Assessment

Clinical Pharmacology &Therapeutics, EarlyView.
An immunogenicity risk assessment (IRA) is a relatively new expectation of health authorities that is increasingly incorporated into the drug development process across the pharmaceutical/biotech industry. The guiding principle for an IRA includes a comprehensive evaluation of product‐ and patient‐related factors that may influence the immunogenic ...
Christine Grimaldi, Susan Richards, Daniel Baltrukonis, Shelley Sims Belouski, Kelly Coble, Sanjay L. Dholakiya, Joanna Grudzinska‐Goebel, Gerry Kolaitis, Jocelyn H. Leu, Linlin Luo, Stephen Lowe, Tao Niu, Henrik Toft‐Hansen, Jianning Yang, Benjamin Wu   +14 more
wiley   +1 more source

Modeling the mechanisms of antibody mixtures in viral infections: the cases of sequential homologous and heterologous dengue infections [PDF]

arXiv
Antibodies play an essential role in the immune response to viral infections, vaccination, or antibody therapy. Nevertheless, they can be either protective or harmful during the immune response. Moreover, competition or cooperation between mixed antibodies can enhance or reduce this protective or harmful effect. Using the laws of chemical reactions, we
arxiv